



Deposited via The University of Sheffield.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/id/eprint/106889/>

Version: Accepted Version

Article:

McKenzie, L., Sazanovich, I., Baggaley, E. et al. (2016) Metal Complexes For Two-photon Photodynamic Therapy: A Cyclometallated Iridium Complex Induces Two-photon Photosensitization of Cancer Cells Under Near-IR Light. *Chemistry - A European Journal*. ISSN: 0947-6539

<https://doi.org/10.1002/chem.201604792>

This is the peer reviewed version of the following article: McKenzie, L. K., Sazanovich, I. V., Baggaley, E., Bonneau, M., Guerchais, V., Williams, J. A. G., Weinstein, J. A. and Bryant, H. E. (2016), Metal Complexes for Two-Photon Photodynamic Therapy: A Cyclometallated Iridium Complex Induces Two-Photon Photosensitization of Cancer Cells under Near-IR Light. *Chem. Eur. J.*, which has been published in final form at <http://doi.org/10.1002/chem.201604792>. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.

Reuse

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.

CHEMISTRY

A European Journal

A Journal of



Accepted Article

Title: Metal Complexes For Two-photon Photodynamic Therapy:
A Cyclometallated Iridium Complex Induces Two-photon
Photosensitization of Cancer Cells Under Near-IR Light

Authors: Luke McKenzie, Igor Sazanovich, Elizabeth Baggaley,
Mickaële Bonneau, Véronique Guerchais, Gareth Williams,
Julia Weinstein, and Helen E Bryant

This manuscript has been accepted after peer review and appears as an Accepted Article online prior to editing, proofing, and formal publication of the final Version of Record (VoR). This work is currently citable by using the Digital Object Identifier (DOI) given below. The VoR will be published online in Early View as soon as possible and may be different to this Accepted Article as a result of editing. Readers should obtain the VoR from the journal website shown below when it is published to ensure accuracy of information. The authors are responsible for the content of this Accepted Article.

To be cited as: *Chem. Eur. J.* 10.1002/chem.201604792

Link to VoR: <http://dx.doi.org/10.1002/chem.201604792>

Supported by
ACES

WILEY-VCH

Metal Complexes For Two-photon Photodynamic Therapy: A Cyclometallated Iridium Complex Induces Two-photon Photosensitization of Cancer Cells Under Near-IR Light

Luke K. McKenzie^{1,2}, Igor V. Sazanovich^{1,2,§}, Elizabeth Baggaley², Mickaële Bonneau^{3,4}, Véronique Guerchais⁴, J. A. Gareth Williams³, Julia A. Weinstein^{2} and Helen E. Bryant^{1*}*

¹Department of Oncology and Metabolism, University of Sheffield, Sheffield S10 2RX, UK

²Department of Chemistry, University of Sheffield, Sheffield S3 7HF, UK

³Department of chemistry, Durham University, Durham DH1 3LE, UK

⁴UMR CNRS 6226, Université de Rennes 1, Institut des Sciences Chimiques de Rennes, Campus de Beaulieu, 35042 Rennes, France

§Current address: Harwell Science Campus, OX11 0QX, UK

CORRESPONDING AUTHORS INFORMATION

*Correspondence should be addressed to HB, tel. +44 (0)114 2759040, fax: +44 114 2795320, E-mail: h.bryant@sheffield.ac.uk or JW, tel: +44 (0)114 2229408, fax: +44-(0)114-22-29436, E-mail: julia.weinstein@sheffield.ac.uk

Accepted Manuscript

ABSTRACT

Photodynamic therapy (PDT) uses photosensitizers (PS) which only become cytotoxic upon light-irradiation. Transition metal complexes are highly promising PS due to long excited state lifetimes, and photostability. However, these complexes usually absorb higher-energy UV/Visible light, whilst the optimal tissue transparency is in the lower-energy NIR region. Two-photon excitation (TPE) can overcome this dichotomy, with simultaneous absorption of two lower-energy NIR-photons populating the same PS-active excited state as one higher-energy photon.

We introduce two low-molecular weight, long-lived and photostable iridium complexes of the $[\text{Ir}(\text{N}^{\wedge}\text{C})_2(\text{N}^{\wedge}\text{N})]^+$ family with high TP-absorption, which localise to mitochondria and lysosomal structures in live cells. The compounds are efficient PS under 1-photon irradiation (405 nm) resulting in apoptotic cell death in diverse cancer cell lines at low light doses (3.6 J cm^{-2}), low concentrations, and photoindexes of up to >555 . Remarkably **1** also displays high PS activity killing cancer cells under NIR two-photon excitation (760 nm), which along with its photostability indicates potential future clinical application.

Main text

Photodynamic therapy (PDT) is a light-activated treatment offering reduced side effects compared to traditional therapy^[1]. The PDT agent, a photosensitizer (PS), is only activated upon targeted irradiation by light of a PS-specific wavelength which promotes the PS to its excited, high-energy state (*PS).

In oxygen-dependent PDT, cellular oxygen and *PS interactions allow excited-state energy transfer, regenerating the ground state of the PS and producing reactive oxygen species (ROS) including singlet oxygen ($^1\text{O}_2$), with subsequent reactions with the intracellular components leading to cell death. Targeted intracellular localisation of the PS is important for maximum effect with organelles situated nearest to *PS being the most affected.^[2]

The photophysical properties of many transition metal complexes make them ideal PS candidates. Their key advantage over organic molecules is the heavy atom effect which favours fast singlet to triplet intersystem crossing (ISC). The longer lifetimes which result from ISC lead to high yields of $^1\text{O}_2$ and/or other ROS. The ease of chemical modification and photostability adds to the appeal of these complexes. Accordingly, an increasing number of transition metal complexes have been investigated for use in PDT including those of Pt(IV), Pt(II), Ru(II), Re(I)^[3] and Ir(III).^[4]

One limitation to the clinical use of metal complexes investigated for PDT has been their absorption of light in the UV/Vis region, whilst the optimal tissue penetration window is 700 – 900 nm. Two-photon excitation (TPE), or two-photon PDT (TP-PDT) can overcome this barrier. Compounds with high PDT activity under one-photon excitation at a particular wavelength in the UV/visible region, should theoretically show PDT-activity under TPE in the low-energy NIR region, with the simultaneous advantages of the range of relative tissue transparency, increased potential depth of tissue penetration, and increased spatial targeting.^[5] TP-PDT requires high two-photon absorption cross-section and exceptional photostability ruling out current clinical photosensitizers. A number transition metal complexes^[3c, 6] have been developed as two-photon agents, some of which have been shown to induce TPE cell killing *in vitro* using cell cultures.^[3c, 6a, 7]

We present here two low-molecular weight, mitochondrial and lysosomal targeting, iridium complexes which display good PS activity under one-photon excitation in a number of cancer cell lines. Remarkably, one of the complexes is also an efficient PS inducing cell death under TPE, and thus displays highly promising results for TP-PDT.

The new iridium complexes **1** and **2** (Figure 1) are members of the $[\text{Ir}(\text{N}^{\wedge}\text{C})_2(\text{N}^{\wedge}\text{N})]^+$ family and closely related to the complex $[\text{Ir}(\text{ppy})_2(\text{pybzH})]^+$.^[8] **1** and **2** feature bis-benzimidazole and its *N,N*-dimethylated derivative, respectively, as the $\text{N}^{\wedge}\text{N}$ ligand (Figure 1). The complexes were prepared as their hexafluorophosphate salts from the chloro-bridged dimer $[\text{Ir}(\text{ppy})_2(\mu\text{-Cl})]_2$, by reaction with 2,2'-bisbenzimidazole or 1,1'-

dimethyl-2,2'-bisbenzimidazole (for **1** and **2** respectively), (S3 – S5). The absorption spectra of **1** and **2** show moderately intense absorption bands in the visible region due to MLCT transitions (Figure S2). The emission quantum yields are 0.33 and 0.24 respectively, Emission lifetimes of the order of a microsecond indicate the triplet nature of the emissive state. Importantly, the complexes phosphoresce intensely also under NIR TPE; and **1** has an appreciable two-photon cross-section of 112 GM at 760 nm (Figure S2).

The TPE phosphorescence imaging of **1** and **2** demonstrate cellular uptake (Figure S3) with cytoplasmic localisation, similar to that of the previously reported bis-cyclometallated iridium complexes.^[4b, 4d] Co-localisation experiments with organelle-specific fluorescent dyes demonstrate mitochondrial and lysosomal localisation. Within 4 h of exposure, mitochondrial localisation is observed with a Pearson's correlation coefficient $r=0.547$ (Figures 2A and S4). Additionally, from 2 h increasing lysosomal staining occurs. By 24 h the lysosomal localisation of **1** becomes dominant with Pearson's correlation coefficients of $r=0.387$ compared to 0.19 for the mitochondrial staining (Figures 2B and S4).

Cellular uptake was not observed at 4°C indicating that **1** is actively taken up rather than entering cells by passive diffusion (Figure S5). A number of cellular uptake pathways were inhibited to determine the uptake route (Figure S5). Only valinomycin, which is known to cause an increase in the membrane potential of cells, had an inhibitory effect on the uptake of **1** (Figure S5). Thus uptake of **1** appears to largely occur via a cell membrane potential-dependent pathway which is consistent with it being a singly-charged cation.

Clonogenic survival assays in the cervical cancer cell line, HeLa demonstrate that **1** and **2** show high light cytotoxicity giving LD₅₀ values of 0.3 μM and 0.5 μM respectively (405 nm, 3.6 J cm⁻²) (Figure 3 and S6). **1** shows low dark cytotoxicity, with an LD₅₀ of >100 μM, whilst **2** shows a much higher dark cytotoxicity, LD₅₀ = 6.2 μM. Comparative PDT activity of a compound can be estimated by the value of the phototoxicity index (PI), $PI = LD_{50}^{dark}/LD_{50}^{light}$. The lowest estimated PI for **1** in HeLa cells is >333, but only 12.4 for **2** due to its high dark cytotoxicity, hence **2** was not investigated further. The increased dark toxicity of **2** compared to **1** is likely due to the presence of N-Me-groups, which would rule out H-bonding and profoundly

affect intermolecular interactions within the cells. **1** also shows photosensitizing effects in a number of cancer cell lines (Figure S6), demonstrating the potential broad applicability of **1** for PDT.

To evaluate the importance of oxygen in cell killing by **1** and **2**, the yield of singlet oxygen generation was measured. In air-equilibrated dichloromethane, high $\Phi(^1\text{O}_2)$ of 42% and 40% for **1** and **2** respectively were determined directly from the emission of the $^1\Delta_g$ state of O_2 in the NIR (λ_{em} 1275 nm) under 355 nm irradiation, demonstrating the ability of the complex to generate singlet oxygen. In a cellular environment, singlet oxygen immediately reacts with the surroundings, from this point of view, the detection of ROS in cells is an important measurement as it confirms an increase of cellular ROS concentration in the presence of the complex. Here, an approximate 8-fold increase in ROS was detected in cells treated with **1** and light (405 nm) compared to cells treated with light alone (Figure S7). Efficient intracellular ROS production and $^1\text{O}_2$ production in solution are suggestive of an oxygen dependant mechanism of cell killing.

The mechanism of cell death was determined to be apoptosis (Figure S6). It is proposed that apoptotic cell death after light treatment is associated with localisation of photosensitizers to both the mitochondria and the lysosomes^[9]. Here similar photosensitizing efficacy is seen when the cells were exposed to light following a 2 hr incubation – where mainly mitochondrial localisation is seen, or a 24 hr incubation – where mainly lysosomal localisation is seen (Figure 3). We therefore suggest that light induced cell death by **1** may be due to disruption of one or both of these organelles, which can trigger apoptotic cell death.

The photosensitizing activity of **1** under TPE with 760 nm light was investigated in HeLa cells (Figure 4). The resulting images show apoptosis (green) and cell death (red) induced by TPE photosensitization. The **1**-exposed cells within the irradiated square clearly show apoptosis/cell death, whilst the surrounding non-irradiated cells do not. Little to no killing of cells is seen in the absence of **1** with light power as high as 25 mW which under these conditions relates to a dose of 2720 J cm^{-2} , this is the lower end of light doses reported to date for two-photon photosensitizers.^[7a-c] This

result therefore demonstrates the potential of **1** as a specific two-photon-activated PS at low concentrations and at doses of light that, alone, are not harmful to cells.

In summary, we introduce two novel small-molecule Ir(III) complexes, which are cell-permeable, easy to synthesize, possess long-lived triplet excited states, high linear absorption cross sections in the visible range, and high two-photon absorption cross sections in the NIR range of the spectrum. **1** has low dark toxicity and is rapidly and actively taken up into a diverse range of cancer cell types, where localisation is primarily in the mitochondria and lysosomes. High PS activity of **1** has been demonstrated in a number of cancer cell lines under one-photon excitation with 405 nm light, with an impressive PI index of >333 and up to 555 depending on cell line (lower limit estimate). Remarkably, **1** is also active in photosensitizing cell death via apoptosis under NIR TPE (760 nm), at low concentrations and light doses.

Overall, the results demonstrate the exciting potential of **1** as a future two-photon PDT agent, and illuminate the potential of Ir(III) complexes as TP-PDT agents.

ACKNOWLEDGMENTS

This work was funded jointly by Yorkshire Cancer Research, Cancer Research UK, BBSRC, EPSRC KTA and MRC POC funds, University of Durham and CNRS (France). Microscopy was performed on equipment purchased by Wellcome Trust grant WT093134AIA and MRC SHIMA award MR/K015753/1

The authors would like to thank Prof. Botchway, Dr Grey, Mr Shewring and Dr Delor for help and advice, and Dr Robinson for help in capturing images.

AUTHOR CONTRIBUTIONS

HB and JW conceived, designed and initiated study. LM performed imaging, 1-photon and 2-photon toxicity assays and ROS production in cells. LM and IS quantified singlet oxygen yields. MB, VG and GW synthesised and characterised compounds. EB performed two photon cross section measurements. LM, JW, EB, GW and HB wrote manuscript.

COMPETING FINANCIAL INTERESTS

The authors declare no competing financial interests.

MATERIALS AND CORRESPONDENCE Helen Bryant and Julia Weinstein

REFERENCES

- [1] A. E. O'Connor, W. M. Gallagher, A. T. Byrne, *Photochemistry and photobiology* **2009**, *85*, 1053-1074.
- [2] A. P. Castano, T. N. Demidova, M. R. Hamblin, *Photodiagnosis and Photodynamic Therapy* **2005**, *2*, 1-23.
- [3] aF. S. Mackay, J. A. Woods, H. Moseley, J. Ferguson, A. Dawson, S. Parsons, P. J. Sadler, *Chemistry-A European Journal* **2006**, *12*, 3155-3161; bF. S. Mackay, J. A. Woods, P. Heringová, J. Kašpárková, A. M. Pizarro, S. A. Moggach, S. Parsons, V. Brabec, P. J. Sadler, *Proceedings of the National Academy of Sciences* **2007**, *104*, 20743-20748; cS. C. Boca, M. Four, A. Bonne, B. Van Der Sanden, S. Astilean, P. L. Baldeck, G. Lemercier, *Chemical Communications* **2009**, 4590-4592; dA. Leonidova, V. Pierroz, R. Rubbiani, J. Heier, S. Ferrari, G. Gasser, *Dalton Transactions* **2014**, *43*, 4287-4294; eK. Wähler, A. Ludewig, P. Szabo, K. Harms, E. Meggers, *European journal of inorganic chemistry* **2014**, *2014*, 807-811; fA. Kastl, S. Dieckmann, K. Wähler, T. Völker, L. Kastl, A. L. Merkel, A. Vultur, B. Shannan, K. Harms, M. Ocker, *ChemMedChem* **2013**, *8*, 924-927; gP. M. Antoni, A. Naik, I. Albert, R. Rubbiani, S. Gupta, P. Ruiz - Sanchez, P. Munikorn, J. M. Mateos, V. Luginbuehl, P. Thamyongkit, *Chemistry-A European Journal* **2015**, *21*, 1179-1183; hC. Mari, V. Pierroz, R. Rubbiani, M. Patra, J. Hess, B. Spingler, L. Oehninger, J. Schur, I. Ott, L. Salassa, *Chemistry-A European Journal* **2014**, *20*, 14421-14436; iA. Frei, R. Rubbiani, S. Tubafard, O. Blacque, P. Anstaett, A. Felgenträger, T. Maisch, L. Spiccia, G. Gasser, *Journal of medicinal chemistry* **2014**, *57*, 7280-7292; jA. Naik, R. Rubbiani, G. Gasser, B. Spingler, *Angewandte Chemie* **2014**, *126*, 7058-7061; kT. Joshi, V. Pierroz, C. Mari, L. Gemperle, S. Ferrari, G. Gasser, *Angewandte Chemie International Edition* **2014**, *53*, 2960-2963; lR. E. Doherty, I. V. Sazanovich, L. K. McKenzie, A. S. Stasheuski, R. Coyle, E. Baggaley, S. Bottomley, J. A. Weinstein, H. E. Bryant, *Scientific reports* **2016**, *6*; mM. G. Walker, P. J. Jarman, M. R. Gill, X. Tian, H. Ahmad, P. A. Reddy, L. McKenzie, J. A. Weinstein, A. J. Meijer, G. Battaglia, *Chemistry-A European Journal* **2016**, *22*, 5996-6000.
- [4] aX. Jiang, N. Zhu, D. Zhao, Y. Ma, *Science China Chemistry* **2015**, 1-13; bY. Li, C.-P. Tan, W. Zhang, L. He, L.-N. Ji, Z.-W. Mao, *Biomaterials* **2015**, *39*, 95-104; cS. P.-Y. Li, C. T.-S. Lau, M.-W. Louie, Y.-W. Lam, S. H. Cheng, K. K.-W. Lo, *Biomaterials* **2013**, *34*, 7519-7532; dL. He, Y. Li, C.-P. Tan, R.-R. Ye, M.-H. Chen, J.-J. Cao, L.-N. Ji, Z.-W. Mao, *Chemical Science* **2015**, *6*, 5409-5418; eR.-R. Ye, C.-P. Tan, L. He, M.-H. Chen, L.-N. Ji, Z.-W. Mao, *Chemical Communications* **2014**, *50*, 10945-10948; fF. Xue, Y. Lu, Z. Zhou, M. Shi, Y. Yan, H. Yang, S. Yang, *Organometallics* **2014**, *34*, 73-77; gD. Maggioni, M. Galli, L. D'Alfonso, D. Inverso, M. V. Dozzi, L. Sironi, M. Iannaccone, M. Collini, P. Ferruti, E. Ranucci, *Inorganic Chemistry* **2015**, *54*, 544-553.
- [5] P. T. So, C. Y. Dong, B. R. Masters, K. M. Berland, *Annual review of biomedical engineering* **2000**, *2*, 399-429.

- [6] aC.-T. Poon, P.-S. Chan, C. Man, F.-L. Jiang, R. N. S. Wong, N.-K. Mak, D. W. Kwong, S.-W. Tsao, W.-K. Wong, *Journal of inorganic biochemistry* **2010**, *104*, 62-70; bA. Colombo, C. Dragonetti, D. Roberto, A. Valore, C. Ferrante, I. Fortunati, A. L. Picone, F. Todescato, J. G. Williams, *Dalton Transactions* **2015**, *44*, 15712-15720; cJ. S. Nam, M.-G. Kang, J. Kang, S.-Y. Park, S. J. C. Lee, H.-T. Kim, J. K. Seo, O.-H. Kwon, M. H. Lim, H.-W. Rhee, T.-H. Kwon, *Journal of the American Chemical Society* **2016**, *138*, 10968-10977.
- [7] aK. M. Scherer, R. H. Bisby, S. W. Botchway, J. A. Hadfield, A. W. Parker, *Journal of biomedical optics* **2015**, *20*, 051004-051004; bE. Dahlstedt, H. A. Collins, M. Balaz, M. K. Kuimova, M. Khurana, B. C. Wilson, D. Phillips, H. L. Anderson, *Organic & biomolecular chemistry* **2009**, *7*, 897-904; cA. Karotki, M. Khurana, J. R. Lepock, B. C. Wilson, *Photochemistry and photobiology* **2006**, *82*, 443-452; dJ. Schmitt, V. Heitz, A. Sour, F. Bolze, P. Kessler, L. Flamigni, B. Ventura, C. S. Bonnet, É. Tóth, *Chemistry–A European Journal* **2016**, *22*, 2775-2786; eJ. Schmitt, V. Heitz, A. Sour, F. Bolze, H. Ftouni, J. F. Nicoud, L. Flamigni, B. Ventura, *Angewandte Chemie International Edition* **2015**, *54*, 169-173; fW. Yang, Q. Zou, Y. Zhou, Y. Zhao, N. Huang, Y. Gu, F. Wu, *Journal of Photochemistry and Photobiology A: Chemistry* **2011**, *222*, 228-235; gY. Zhao, W. Wang, F. Wu, Y. Zhou, N. Huang, Y. Gu, Q. Zou, W. Yang, *Organic & biomolecular chemistry* **2011**, *9*, 4168-4175; hH. Huang, B. Yu, P. Zhang, J. Huang, Y. Chen, G. Gasser, L. Ji, H. Chao, *Angewandte Chemie* **2015**, *127*, 14255-14258; iE. M. Boreham, L. Jones, A. N. Swinburne, M. Blanchard-Desce, V. Hugues, C. Terryn, F. Miomandre, G. Lemerrier, L. S. Natrajan, *Dalton Transactions* **2015**, *44*, 16127-16135.
- [8] L. Murphy, A. Congreve, L.-O. Pålsson, J. G. Williams, *Chemical Communications* **2010**, *46*, 8743-8745.
- [9] H. Abrahamse, M. R. Hamblin, *Biochemical Journal* **2016**, *473*, 347-364.

SCHEME AND FIGURE LEGENDS


Figure 1. Complexes 1 and 2.

Figure 2. Sub-cellular localisation of 1. U2OS cells following 4 or 24 hour incubation with **1** (*green*), colocalised with (A) Mitotracker orange (*red*) or (B) LysoTracker (*red*). Zoomed sections are shown as insets. Scale bars = 20 μm .




Figure 3 One-photon-induced PS activities of complexes 1 and 2. (A) Survival of HeLa cells pre-incubated for 2 or 24 h with complexes 1 or 2 +/- light. (B) Annexin V staining in HeLa cells (C) Survival of bladder (EJ), osteosarcoma (U2OS), melanoma (A375) and colorectal (HCT116) cancer cells 1 +/- light treatment.




Figure 4 Two-photon-induced PS activity of 1. HeLa cells treated with **1** or DMSO 2 h before irradiation of a central square with 760 nm multiphoton laser. After 24h cells were stained with markers for apoptosis (Annexin V – red) and cell death (propidium iodide - green). All images are 450x450 μm except those in the 0 mW column which are 900x900 μm .





TABLE OF CONTENTS



Two low-molecular weight, long-lived and photostable iridium complexes of the $[\text{Ir}(\text{N}^{\text{C}})_2(\text{N}^{\text{N}})]^+$ family with high TP-absorption, are shown to localise to mitochondria and lysosomal structures in live cells. The compounds are efficient PS under 1-photon irradiation (405 nm) with photoindexes of up to >555 . Remarkably 1 also displays high PS activity under NIR two-photon excitation (760 nm) indicating potential future clinical application.

KEY WORDS

Cancer therapy, singlet oxygen, Iridium, transition metal complexes, two-photon photodynamic therapy